With its planned acquisition of Biscayne Neurotherapeutics, Supernus Pharmaceuticals ($SUPN) adds a Phase I epilepsy candidate to its portfolio of CNS treatments: http://ow.ly/Q6DP30lP4zt 

17:55 EDT 14 Sep 2018 | Genetic Engineering News

With its planned acquisition of Biscayne Neurotherapeutics, Supernus Pharmaceuticals ($SUPN) adds a Phase I epilepsy candidate to its portfolio of CNS treatments: http://ow.ly/Q6DP30lP4zt 

More From BioPortfolio on "With its planned acquisition of Biscayne Neurotherapeutics, Supernus Pharmaceuticals ($SUPN) adds a Phase I epilepsy candidate to its portfolio of CNS treatments: http://ow.ly/Q6DP30lP4zt "